Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to a preclinical study led by Roswell Park. Results of the study, led by Sayan Chakraborty, PhD, Assistant Professor of Oncology at Roswell Park, appear in Advanced Science.

Thomas B. Tomasi Jr., MD, PhD, who led Roswell Park as President and CEO from 1986-1996, died March 23, 2025, at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers.

A clinical research study led by Roswell Park experts outlines a new way to measure pain in cancer patients and treat it effectively without opioids. The new study advances the goal of better managing cancer pain by incorporating both non-invasive brain imaging technology and virtual reality (VR).

Cancer surgery leaders from Roswell Park will share their expertise with other cancer surgeons from around the world during the annual meeting of the Society of Surgical Oncology at the Tampa Convention Center March 27-29.